Logo

FMCNA's Novalung ECMO System Receives the US FDA's Approval for Acute Respiratory and Cardiopulmonary Failure

Share this

FMCNA's Novalung ECMO System Receives the US FDA's Approval for Acute Respiratory and Cardiopulmonary Failure

Shots:

  • The US FDA has cleared the Novalung system which eliminates the need for mechanical ventilation by pumping a person’s blood through an oxygenator for gas exchange
  • Novalung is the first extracorporeal membrane oxygenation (ECMO)- approved to provide for more than 6hrs. of use as extracorporeal life support with its anticipated availability in the US in mid-2020
  • The Novalung ECMO system works by pumping and oxygenating a patient's blood- reducing the stress on the damaged heart and lungs. Novalung is a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as ICU- OT- cardiac catheterization labs and emergency departments

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fresenius Medical Care North America


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions